SHOO · Steven Madden, Ltd.

Current Thesis

The "worst-of-tariffs-is-behind-us" recovery in SHOO is played out, not accelerating, and the tape now carries a distribution tell on top of it. The stock round-tripped from its ~$22 April-2025 tariff-crash low back to ~$43.40 (trading $43.35–$43.65 on 2026-06-03) and has stalled in the top decile of its 52-wk range ($22.26–$46.88), within ~7% of the $46.88 high. Q1 (reported 2026-05-06) printed +18.0% revenue YoY to $653.1M, but that headline is almost entirely the $360M Kurt Geiger acquisition (DTC +83.8% to $206.0M); organic DTC was only +8.0%, and adjusted diluted EPS fell to $0.45 from $0.60 a year ago. The $1.00 GAAP EPS was flattered by a one-time $55.1M pre-tax tariff-recovery benefit. This is a maturing, sell-side-consensus turnaround a legacy supply-chain pivot dressed up by M&A and a tax-credit windfall not the fresh accelerating leg this book exists to catch.

Bull Case

• Supply-chain de-risking executed, not promised. China fell from 71% of US imports (2024) to an expected <10% by spring 2026 ex-Kurt Geiger, via CAFTA nearshoring plus Vietnam/Cambodia/Brazil the tariff-insulation the market feared SHOO couldn't pull off (Q1 call, 2026-05-06).
• Guidance raised on the Q1 call (2026-05-06): FY2026 revenue to +10–12% (from +9–11%), GAAP EPS $2.55–$2.65, adjusted EPS $2.00–$2.10. A raise into a tariff backdrop is a credibility signal.
• Kurt Geiger accretion building. The $360M deal (closed May 2025) drove DTC +83.8% to $206.0M in Q1; management guides Kurt Geiger China sourcing sharply lower for Spring 2026, reducing its tariff drag.
• Sell-side bulls nudging higher: Williams Trading raised its target to $52 from $48 (Buy) after the print; BTIG reiterated Buy / $50 (2026-06-04). Management ran institutional meetings (Piper, Telsey, BTIG, Needham) in early June 2026.
• New distribution shoots: Macy's concessions and India expansion were flagged as 2026 growth levers on the Q1 call optionality if they convert to numbers.

Bear Case

• Adjusted EPS is declining: $0.45 in Q1 vs $0.60 a year ago, and the FY2026 adjusted guide of $2.00–$2.10 sits below 2025. The growth is inorganic; core organic DTC was only +8.0%. The buyer at $43 is paying up for decelerating real earnings masked by M&A and a non-recurring tariff credit.
• a director sold $20,814 on 2026-06-04; No insider conviction at the top of the range.
• Priced to consensus. The 7-analyst consensus PT sits near $42.43 roughly at spot, no margin of safety. UBS anchors at Neutral / $40 (2026-06-03), below market. The $50–$52 Buy targets are the outliers, not the base case.
• Tariff relief is now consensus, not edge. "Worst is behind us" was the April-2025 trade at $22; at $43–44 it is widely understood. FOB costs running 10–15% above old China pricing are a permanent margin headwind, and ~10% list-price increases only partially offset them.
• No accelerant in the tape. Discretionary footwear is cyclically exposed, and this is a recovered name at range highs with no directional catalyst for 60+ days the late-cycle geometry of a turnaround that already worked.

Setup & Price Structure

Spot ~$43.40 (intraday $43.35–$43.65 on 2026-06-03), flat over the past week and sitting in the top decile of the $22.26–$46.88 52-wk range, ~7% under the high. The stock has roughly doubled off the April-2025 tariff low, so the easy mean-reversion leg is finished. Price is above its rising moving averages but extended within the recovery rather than basing for a fresh breakout there is no new shelf above $46.88 to break into blue sky. The near-term structure to watch on the downside is the rising 20-EMA near $40 and the $39 prior-shelf; below those, the round-trip reverses. This is the classic "was a great idea at $22, is it still at $44?" re-rate question, answered into a stalled tape with insider supply hitting the bid at the highs.

Catalyst Calendar (next 30 days)

• 2026-06-08 Dividend record date ($0.21/sh). A cash event for holders of record, not a directional price catalyst.
• 2026-06-19 Dividend pay date ($0.21/sh). Cash distribution, no price signal.
• Ongoing through June Institutional meeting cadence (Piper, Telsey, BTIG, Needham early-June) can produce incremental notes, but no scheduled binary. Williams Trading $52 / UBS $40 already set the near-term sell-side bookends.
• No earnings, FDA, or product binary inside 30 days. The next real catalyst is the Q2 print, estimated ~early August 2026 (>30 days out), which is where the maturing-recovery read gets tested against the $2.00–$2.10 adjusted-EPS guide.

What Would Change Our Mind

• Bullish re-rate: organic ex-Kurt-Geiger DTC re-accelerating above the +8% Q1 pace, a Q2 (~Aug 2026) raise to the adjusted-EPS guide above $2.10, or a clean breakout and weekly hold above the $46.88 52-wk high turning the stalled range into a base all of which would argue the pivot is compounding, not just recovering.
• Bearish confirmation / thesis break: a weekly close below the rising 20-EMA (~$40) or loss of the $39 shelf reversing the round-trip; the ~Aug Q2 print cutting the $2.00–$2.10 adjusted-EPS guide; organic ex-Kurt-Geiger DTC turning negative; or continued insider selling expanding into a heavier cluster.
• The fresh-entry case only improves on a pullback toward MA support with the narrative intact chasing a maturing recovery at consensus targets, with insiders selling, is the trap to avoid.

Correlation Notes

• Theme: consumer-cyclical-rotation (MATURING) and tariff-supply-chain-reshoring. SHOO trades with discretionary-retail risk appetite; a consumer-spending wobble hits a top-of-range name hardest.
• Tariff/sourcing peers: moves with the broader footwear/apparel reshoring cohort (Crocs, Skechers, Deckers, Wolverine) on tariff and China-sourcing headlines the structural China-cut story is sector-wide, not SHOO-specific edge.
• Macro sensitivity: rate-cut/soft-landing tape supports discretionary multiples; a tightening or consumer-weakness regime is the macro invalidation for the whole rotation. FX matters via Kurt Geiger's UK/Europe exposure.
• M&A overhang: the growth narrative is now levered to Kurt Geiger integration; a stumble there hits the headline harder than the organic Steven Madden base would suggest.